Shrink the pa­tient group, boost the ef­fi­ca­cy: Tonix says a retro look shows promise in se­lect PTSD group

A back­wards glance at tri­al da­ta — and a reshuf­fling of the pa­tients in­volved — has re­vert­ed fail­ure to op­ti­mism for Tonix Phar­ma­ceu­ti­cals. At least that’s what com­pa­ny ex­ecs are root­ing for, ac­cord­ing to an up­date they’ve pro­vid­ed to­day on its PTSD drug Ton­mya.

You might re­mem­ber Ton­mya for the re­cent Phase III tri­al flop that washed Tonix’s stock in­to the gut­ter, sink­ing the share price near­ly 70% over the past four weeks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.